“…In cancer, ROS produced by myeloid-derived suppressor cells are assumed to inhibit cytotoxic T cell responses (26,27); in contrast, a reduced ROS production in mice with an allelic polymorphism in Ncf1, which encodes a component of the ROSgenerating NADPH oxidase, entails increased T cell thiol expression, dysfunctional elimination of autoreactive T cells, and development of autoimmunity (16,28,29). In several chronic infections, in particular HIV infection, there is an imbalance in the redox status of T cells, with ensuing dysfunction and apoptosis in T cell subsets (30)(31)(32). Collectively, these previous studies highlighted that the redox balance of T cells is critical for T cell function and survival and point to the possibility of controlling thiols and, hence, modulating T cell function and survival, by pharmacological intervention (30,32).…”